UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the importance of long-term monitoring. A recent study reveals CAR T-cell therapy ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that could put some pressure on CAR T-cell therapies, including the company’s own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results